A recent study testing the impact of microdosing LSD has suggested the practice has no therapeutic or cognitive effects.
Last week Italy’s Constitutional Court blocked the country’s campaign calling for the decriminalisation of psychotropic substance cultivation.
A new collaboration will investigate the efficacy of EVM-101, a first-generation psychedelic treatment, for the treatment of Cancer Related Distress (CRD).
New results have demonstrated treating major depressive disorder (MDD) with psilocybin-assisted psychotherapy is effective for up to a year in some patients.
The philanthropic arm of atai Life Sciences, atai Impact, has donated $500,000 to The Multidisciplinary Association for Psychedelics (MAPS) for multi-year support of MAPS’ ongoing initiatives,...
Historically dubbed the “love drug” for its ability to induce sensual feelings and pro-social behaviour, MDMA is now being researched for a number of social and...
Some patients hospitalised with severe suicidal thoughts could benefit from ketamine treatment.
A subcommittee of the Oregon Psilocybin Advisory Board (OPAB) is considering whether to provide special protections for religious practises involving the use of psilocybin.
A group of scientists have reported findings that provide a foundation for the structure-based design of safe and effective non-hallucinogenic, rapid-acting antidepressants.
With the industry fast developing, trained professionals are vital for the delivery of psychedelic healthcare.
A Phase I clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of DMT will further research into the compound’s therapeutic potential.
“Psilocybin products may be unregulated and even illegal in many markets, but producers of psilocybin are more conscious of the consumer than the cannabinoid industry appears...
